Super Enhancer Regulatory Gene FYB1 Promotes the Progression of T Cell Acute Lymphoblastic Leukemia by Activating IGLL1

Kunlong Zhang, Jun Lu, Fang Fang, Yongping Zhang, Juanjuan Yu, Yanfang Tao, Wenyuan liu, Lihui Lu, Zi-Mu Zhang, Xinran Chu, Jianwei Wang, Xiaolu Li, Yuanyuan Tian, Zhiheng Li, Qian Li, Xu Sang, Li Ma, Ningling Wang, Jian Pan, Shaoyan HuJournal of Immunology Research 2023 · DOI

TL;DR

This study identifies FYB1 as a key driver in T-cell acute lymphoblastic leukemia (T-ALL) progression, regulated by super-enhancers. FYB1 promotes T-ALL by activating IGLL1, suggesting this FYB1-IGLL1 axis as a potential therapeutic target for this aggressive cancer.

What Problem Does This Paper Address?

T-cell acute lymphoblastic leukemia (T-ALL) is a challenging hematologic malignancy with poor treatment outcomes, especially in relapsed cases. While super-enhancers (SEs) are known to play critical roles in cancer pathogenesis by regulating lineage-specific genes and oncogenes, their specific involvement in T-ALL has not been fully elucidated. Furthermore, the precise molecular mechanisms driving T-ALL progression, particularly the role of genes like FYB1, remain poorly understood, hindering the development of more effective therapies. This paper aims to uncover the role of SEs in T-ALL and identify key genes, like FYB1, that contribute to the disease's progression, with the ultimate goal of finding new therapeutic targets.

Methods

The researchers employed a multi-pronged approach:

  • Super-Enhancer Identification: They analyzed public H3K27ac ChIP-seq data from T-ALL cell lines, acute myeloid leukemia (AML) cell lines, and hematopoietic stem and progenitor cells (HSPCs) to identify SEs. The ROSE method was used for SE identification.
  • Gene Expression Analysis: RNA-sequencing (RNA-seq) was performed on T-ALL cells with and without FYB1 knockdown to identify differentially expressed genes (DEGs). Public databases like the Cancer Cell Line Encyclopedia (CCLE) were used to assess gene expression levels across various cell types.
  • Gene Knockdown and Overexpression: Lentiviral shRNAs were used to knockdown FYB1 and IGLL1 in T-ALL cell lines. Overexpression of FYB1 was also performed.
  • Functional Assays:
    • Cell Proliferation and Viability: Cell Counting Kit-8 (CCK8) assays and imaging were used to assess cell growth.
  • Apoptosis: Annexin V/PI staining followed by flow cytometry was used to measure apoptosis. Western blotting was used to detect apoptosis-related proteins (PARP, cleaved caspase-3, and caspase-8).
  • Cell Cycle Analysis: Flow cytometry was used to analyze cell cycle distribution.
  • In Vivo Xenograft Model: A mouse model was established by injecting luciferase-expressing T-ALL cells (with or without FYB1 knockdown) into NSG mice. Tumor burden was monitored using in vivo fluorescence imaging, and survival rates were assessed.

Datasets

  • Public ChIP-Seq Data: H3K27ac ChIP-seq datasets for T-ALL cell lines, AML cell lines, and HSPCs were downloaded from the Cistrome database (GSE70734, GSE29611, GSE50622, GSE76783, GSE59657, GSE80779, GSE123872, GSE188750, GSE71809, GSE70660, and GSE93372).
  • Cancer Cell Line Encyclopedia (CCLE) Database: Used to obtain mRNA expression levels of FYB1 and IGLL1 across various tumor cell lines.
  • RNA-Seq Data: Generated in-house for J-gammal cells with or without FYB1 knockdown (GEO ID: GSE197450).

Key Insights and Ideas

  • SEs are Enriched in T-ALL Oncogenes: The study found that SEs are significantly enriched at the loci of genes known to be involved in T-ALL pathogenesis, such as CDK6, CCND3, and ETV6, suggesting SEs play a crucial role in regulating these key oncogenes in T-ALL.
  • FYB1 is an SE-Driven Gene in T-ALL: FYB1 was identified as a gene directly regulated by SEs in T-ALL cell lines, and its expression was significantly higher in T-ALL cells compared to other cancer types. This points to a specific dependency of T-ALL on FYB1.
  • FYB1 Promotes T-ALL Progression: Knocking down FYB1 significantly inhibited T-ALL cell proliferation and induced apoptosis both in vitro and in vivo, while FYB1 overexpression enhanced proliferation. This strongly implicates FYB1 as a promoter of T-ALL growth and survival.
  • IGLL1 is a Downstream Effector of FYB1: The study identified IGLL1 as a key downstream target of FYB1. FYB1 knockdown led to decreased IGLL1 expression, and IGLL1 knockdown mimicked the effects of FYB1 knockdown, inhibiting proliferation and promoting apoptosis in T-ALL cells.
  • FYB1-IGLL1 Axis as a Therapeutic Target: The findings highlight the FYB1-IGLL1 signaling axis as a critical pathway for T-ALL cell self-renewal and survival, presenting it as a promising therapeutic target for T-ALL patients.

Key Results

  • FYB1 Knockdown: Significantly inhibited T-ALL cell proliferation (P<0.001) and enhanced apoptosis in J-gammal and 6T-CEM cell lines.
  • In Vivo Studies: Downregulation of FYB1 significantly decreased disease burden, suppressed tumor growth, and improved survival rates in a mouse xenograft model (survival increased from 38±1.2 days to 43±2.0 days, P=0.0026).
  • IGLL1 Expression: Knocking down FYB1 led to a significant decrease in IGLL1 expression. IGLL1 was found to be highly expressed in T-ALL.
  • IGLL1 Knockdown: Significantly inhibited T-ALL cell proliferation and promoted apoptosis, similar to FYB1 knockdown.
  • Apoptosis Markers: Downregulation of FYB1 led to increased levels of PARP, cleaved caspase-3, and caspase-8, indicating increased apoptosis.

Limitations and Future Work

  • Direct Regulatory Relationship: While the study strongly suggests a regulatory relationship between FYB1 and IGLL1, the authors note that further efforts, such as FYB1 ChIP-seq, are warranted to definitively show the direct regulatory relationship.
  • Broader Functional Studies of IGLL1: The function of IGLL1 is largely unknown, and while this study shows its importance in T-ALL, more extensive functional studies could further elucidate its role.
  • Therapeutic Translation: While the FYB1-IGLL1 axis is proposed as a therapeutic target, further research would be needed to develop and test specific inhibitors or modulators of this pathway in clinical settings.

Summary updated

Abstract

Our results suggested that FYB1 gene played important role in regulating self-renewal of T-ALL cells by activating IGLL1, representing a promising therapeutic target for T-ALL patients.
BibTeX
@article{zhang2023super,
  author = {Kunlong Zhang and Jun Lu and Fang Fang and Yongping Zhang and Juanjuan Yu and Yanfang Tao and Wenyuan liu and Lihui Lu and Zi-Mu Zhang and Xinran Chu and Jianwei Wang and Xiaolu Li and Yuanyuan Tian and Zhiheng Li and Qian Li and Xu Sang and Li Ma and Ningling Wang and Jian Pan and Shaoyan Hu},
  title = {{Super Enhancer Regulatory Gene FYB1 Promotes the Progression of T Cell Acute Lymphoblastic Leukemia by Activating IGLL1}},
  journal = {Journal of Immunology Research},
  year = {2023},
  doi = {10.1155/2023/3804605},
}
Figure